J. Biol. Chem., Vol. 266, Issue 36, 24359-24366, Dec, 1991

Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S

E Ido, HP Han, FJ Kezdy and J Tang
Protein Studies Program, Oklahoma Medical Research Foundation, Oklahoma City 73104.

Human immunodeficiency virus type 1 (HIV-1) protease optimally catalyzes in the pH range of 4-6 in contrast to nearly all of the other eukaryotic aspartic proteases, which catalyze best in the pH range of 2- 4. A possible structural reason for the higher optimal pH of HIV-1 protease is the absence of a hydrogen bond to the carboxyl group of active-site Asp25, which is nearly universally present in others. To investigate this hypothesis, we have mutated residue 28 in HIV-1 protease from alanine to serine. Both the wild-type and the mutant A28S enzymes have been overexpressed in Escherichia coli using a chemically synthesized gene and purified for a comparative study in enzyme kinetics. The kcat and Km values were determined by a radiometric assay for the wild-type enzyme from pH 3.2 to 7.0, and for the mutant enzyme from pH 3.2 to 6.0. The low pK values of the active site of the free enzyme, pKe1, are 3.3 and 3.4 for the wild-type and mutant enzymes, respectively. The low pK values of the active site of the enzyme bound to substrate, pKes1, are 5.1 and 4.3 for the wild-type and mutant enzymes, respectively. The high pK values of the free enzyme, pKe2, are 6.8 and 5.6, and the corresponding ones for the substrate-bound enzyme, pKes2, are 6.9 and 6.0 for the wild-type and mutant enzymes, respectively. The lowering of pK values in mutant HIV-1 protease indicates that the hydroxyl group of Ser28 forms a new hydrogen bond to active-site Asp25 to increase its acidity.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. E. Klei, K. Kish, P.-F. M. Lin, Q. Guo, J. Friborg, R. E. Rose, Y. Zhang, V. Goldfarb, D. R. Langley, M. Wittekind, et al. X-Ray Crystal Structures of Human Immunodeficiency Virus Type 1 Protease Mutants Complexed with Atazanavir J. Virol., September 1, 2007; 81(17): 9525 - 9535. [Abstract] [Full Text] [PDF]

				A. Feher, P. Boross, T. Sperka, G. Miklossy, J. Kadas, P. Bagossi, S. Oroszlan, I. T. Weber, and J. Tozser Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease. J. Gen. Virol., May 1, 2006; 87(Pt 5): 1321 - 1330. [Abstract] [Full Text] [PDF]

				J. Yanchunas Jr., D. R. Langley, L. Tao, R. E. Rose, J. Friborg, R. J. Colonno, and M. L. Doyle Molecular Basis for Increased Susceptibility of Isolates with Atazanavir Resistance-Conferring Substitution I50L to Other Protease Inhibitors Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3825 - 3832. [Abstract] [Full Text] [PDF]

				R. E. Georgescu, E. G. Alexov, and M. R. Gunner Combining Conformational Flexibility and Continuum Electrostatics for Calculating pKas in Proteins Biophys. J., October 1, 2002; 83(4): 1731 - 1748. [Abstract] [Full Text] [PDF]

				B. S. Robinson, K. A. Riccardi, Y.-f. Gong, Q. Guo, D. A. Stock, W. S. Blair, B. J. Terry, C. A. Deminie, F. Djang, R. J. Colonno, et al. BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents Antimicrob. Agents Chemother., August 1, 2000; 44(8): 2093 - 2099. [Abstract] [Full Text]

				H. Tjalsma, G. Zanen, G. Venema, S. Bron, and J. M. van Dijl The Potential Active Site of the Lipoprotein-specific (Type II) Signal Peptidase of Bacillus subtilis J. Biol. Chem., October 1, 1999; 274(40): 28191 - 28197. [Abstract] [Full Text] [PDF]

				D. B. Olsen, M. W. Stahlhut, C. A. Rutkowski, H. B. Schock, A. L. vanOlden, and L. C. Kuo Non-active Site Changes Elicit Broad-based Cross-resistance of the HIV-1 Protease to Inhibitors J. Biol. Chem., August 20, 1999; 274(34): 23699 - 23701. [Abstract] [Full Text] [PDF]

				J. M. Louis, E. M. Wondrak, A. R. Kimmel, P. T. Wingfield, and N. T. Nashed Proteolytic Processing of HIV-1 Protease Precursor, Kinetics and Mechanism J. Biol. Chem., August 13, 1999; 274(33): 23437 - 23442. [Abstract] [Full Text] [PDF]

				C. Nessi, M. J. Jedrzejas, and P. Setlow Structure and Mechanism of Action of the Protease That Degrades Small, Acid-Soluble Spore Proteins during Germination of Spores of Bacillus Species J. Bacteriol., October 1, 1998; 180(19): 5077 - 5084. [Abstract] [Full Text]

				Y. S. Ding, S. M. Owen, R. B. Lal, and R. A. Ikeda Efficient Expression and Rapid Purification of Human T-Cell Leukemia Virus Type 1 Protease J. Virol., April 1, 1998; 72(4): 3383 - 3386. [Abstract] [Full Text] [PDF]

				H. B. Schock, V. M. Garsky, and L. C. Kuo Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical Trials. COMPENSATORY MODULATIONS OF BINDING AND ACTIVITY J. Biol. Chem., December 13, 1996; 271(50): 31957 - 31963. [Abstract] [Full Text] [PDF]

				Z.án Szeltner and Lás. Polgár Conformational Stability and Catalytic Activity of HIV-1 Protease Are Both Enhanced at High Salt Concentration J. Biol. Chem., March 8, 1996; 271(10): 5458 - 5463. [Abstract] [Full Text] [PDF]

				L. Menéndez-Arias, I. T. Weber, and S. Oroszlan Mutational Analysis of the Substrate Binding Pocket of Murine Leukemia Virus Protease and Comparison with Human Immunodeficiency Virus Proteases J. Biol. Chem., December 8, 1995; 270(49): 29162 - 29168. [Abstract] [Full Text] [PDF]

				Z. Chen, Y. Li, H. B. Schock, D. Hall, E. Chen, and L. C. Kuo Three-dimensional Structure of a Mutant HIV-1 Protease Displaying Cross-resistance to All Protease Inhibitors in Clinical Trials J. Biol. Chem., September 15, 1995; 270(37): 21433 - 21436. [Abstract] [Full Text] [PDF]